이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Integration of Wearable Sensor Devices Into a Single System to Predict the Onset of Sepsis (IRHIS)

2026년 5월 12일 업데이트: Check Point R & D Ltd
The purpose of this clinical investigation is to evaluate the integration of data from the CPC12S telemonitoring device, the CPC temperature/humidity sensor, and the IDRO sweat lactate sensor into a single system for the prediction of sepsis onset in ICU patients at risk of developing sepsis. Patients will be monitored for up to 48 hours, and the collected physiological and biomarker data will be used to support the development of artificial intelligence and machine learning models for sepsis prediction.

연구 개요

상세 설명

This is a prospective clinical performance study involving ICU patients at risk of developing sepsis. The study will assess the integration of portable sensor devices into the CPC telemonitoring platform for the collection and visualization of physiological and biomarker data.

The CPC12S device will collect vital physiological parameters, including electrocardiography, oxygen saturation, non-invasive blood pressure, respiratory rate, heart rate, body position, and physical activity. A CPC temperature and humidity sensor will be used for continuous monitoring of body temperature and humidity. In addition, the IDRO investigational sweat lactate sensor will be integrated into the system to collect sweat lactate data.

The study will be conducted in phases. In the first phase, patients will be monitored using the CPC12S device together with the temperature and humidity sensor. In the second phase, patients will be monitored using the CPC system, the temperature and humidity sensor, and the IDRO sweat lactate sensor.

All patients will be monitored for up to 48 hours. The collected data will be analyzed together with clinical information recorded by healthcare professionals. The primary objective is to support prediction of sepsis onset by integrating data from the CPC12S device, the CPC temperature/humidity sensor, and the IDRO sweat lactate sensor. Secondary objectives include completing the integration of the IDRO sensor into the CPC system, validating the IDRO sweat lactate measurements against standard clinical blood lactate measurements, and developing an algorithm based on device-recorded and clinical data for sepsis prediction.

The data collected in this study will not be used to guide clinical decisions during the study. Medical care and clinical decisions will remain under the responsibility of the hospital medical team according to standard clinical practice.

연구 유형

중재적

등록 (추정된)

360

단계

  • 해당 없음

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

아니

설명

Inclusion Criteria:

  • Adult patients aged 18 years or older.
  • Patients admitted to the intensive care unit who are at risk of developing sepsis.
  • Patients with one or more relevant risk factors for sepsis, including pre-existing medical conditions, invasive medical devices, recent procedures or conditions, active infections, clinical risk factors, or prolonged ICU/hospital stay.
  • Signed informed consent.Exclusion Criteria:
  • Inability or unwillingness to provide informed consent or comply with study requirements.
  • ICU stay shorter than 6 hours.
  • Damaged tattoos, bare skin, recent scar tissue, inflammation, infection, skin barrier alteration, serous or bloody discharge, or metal plates/nails at the area where the Macroduct Advanced system and IDRO device will be placed.
  • Patients admitted to the ICU with already diagnosed sepsis.
  • Patients participating in other clinical studies.
  • Moribund patients or patients with very short life expectancy.
  • Patients with do-not-resuscitate status at admission.
  • Patients with implanted devices such as an implanted defibrillator, implanted neurostimulator, implanted pacemaker, or implanted ECG monitor.
  • Patients in whom short-term interference between the Macroduct device and clinical monitoring cannot be accepted.
  • Patients with a history of epilepsy or seizures.
  • Pregnant patients or patients who may be pregnant.
  • Patients with previous adverse reactions to electrotherapy.
  • Patients who present adverse reactions during the first sampling with the Macroduct device.
  • Patients for whom the procedure is contraindicated for medical reasons according to the physician's decision.
  • Patients with known sensitivity or allergy to pilocarpine nitrate, or any medical contraindication to pilocarpine administration.
  • Patients in environments with flammable anesthetics or oxygen-enriched environments.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 방지
  • 할당: 무작위화되지 않음
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: CPC12S + Temperature/Humidity Sensor
Participants will be monitored using the CPC12S telemonitoring device together with the CPC temperature and humidity sensor. Data will include physiological parameters, body temperature, and humidity during ICU monitoring.
The CPC12S telemonitoring system will be used together with the CPC temperature and humidity sensor to collect physiological parameters, body temperature, and humidity data from ICU patients during the monitoring period.
실험적: CPC12S + Temp/Humidity + IDRO Sensor
Participants will be monitored using the CPC12S telemonitoring system together with the CPC temperature and humidity sensor and the investigational IDRO sweat lactate sensor. Data will include physiological parameters, temperature, humidity, and sweat lactate measurements.
The CPC12S telemonitoring system will be used together with the CPC temperature and humidity sensor to collect physiological parameters, body temperature, and humidity data from ICU patients during the monitoring period.
The investigational IDRO sweat lactate sensor will be used to collect sweat lactate measurements. The sensor will be integrated with the CPC system for data transmission, visualization, and analysis.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Area under the receiver operating characteristic curve (AUC-ROC) of the integrated sensor-based model for prediction of sepsis onset
기간: Up to 48 hours of patient monitoring
The primary outcome is the predictive performance of the integrated sensor-based model for identifying sepsis onset in ICU patients. The model will use data collected from the CPC12S telemonitoring system, the CPC temperature/humidity sensor and, where applicable, the IDRO sweat lactate sensor. Sepsis onset will be determined by the clinical diagnosis recorded by the treating medical team and assessed according to Sepsis-3 criteria. Predictive performance will be reported as the area under the receiver operating characteristic curve (AUC-ROC).
Up to 48 hours of patient monitoring

2차 결과 측정

결과 측정
측정값 설명
기간
Correlation between IDRO sweat lactate measurements and standard blood lactate measurements
기간: Up to 48 hours of patient monitoring
The correlation between sweat lactate values measured by the IDRO sensor and blood lactate values measured as part of routine ICU clinical practice will be assessed using Pearson or Spearman correlation coefficients.
Up to 48 hours of patient monitoring

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 7월 1일

기본 완료 (추정된)

2027년 3월 1일

연구 완료 (추정된)

2027년 3월 1일

연구 등록 날짜

최초 제출

2026년 5월 5일

QC 기준을 충족하는 최초 제출

2026년 5월 12일

처음 게시됨 (실제)

2026년 5월 19일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 5월 19일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 5월 12일

마지막으로 확인됨

2026년 5월 1일

추가 정보

이 연구와 관련된 용어

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다